Sonnet BioTherapeutics appoints McAndrew as CBO, Griffith as CFO

The Company has promoted Dr. Stephen McAndrew from his role as Senior Vice President, Business Development, to Chief Business Officer, CBO, to enhance its focus on business development, effective February 17, 2025. Jay Cross submitted his resignation as Chief Financial Officer, effective February 21, 2025. Cross will be succeeded by Donald Griffith, CPA, who has been promoted as the new Chief Financial Officer from his role as Controller, effective February 21, 2025. This update to the Company’s leadership team will preserve a continued focus on advancing business development opportunities while remaining vigilant on cost controls.